Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears

Suvretta Capital increased its stake in Mineralys Therapeutics (MLYS) by 387,641 shares in Q3, bringing holdings to 2.13 million shares worth $80.85 million as of Sept. 30 and representing ~2.07% of the fund's 13F AUM. Mineralys shares recently traded at $36.96, up ~206% year-over-year, and the company reported $593.6 million in cash following a $287.5 million equity raise, which management says funds operations into 2028; the company is advancing lead asset lorundrostat toward an NDA submission targeted by early 2026. Latest quarterly net loss narrowed to $36.9 million and TTM net loss is ($171.36M), underscoring a clinical-stage biotech transitioning from trial execution to regulatory positioning.

Analysis

Market structure: Suvretta’s $57M buy into MLYS amid a 206% YTD rally (price $36.96, market cap $2.93B) signals concentrated institutional demand into a single pre‑approval asset (lorundrostat). Winners are equity holders, option holders (long calls), and suppliers (CROs, CDMOs) if development continues; losers would be short sellers and competitive late‑stage programs that face re‑rating risk. Cross‑asset: expect elevated implied volatility in MLYS options (where directional flow will concentrate), modest spillover into small‑cap biotech credit spreads, and limited FX/commodity impact.

Risk assessment: Key tail risks are FDA non‑approval or safety signals (binary regulators) and commercialization/payer failure post‑approval; assign high impact but low probability within 12–18 months. Time horizons: immediate (days) = momentum/liquidity-driven moves; short (3–12 months) = NDA submission visibility (management targets early 2026); long (12–36 months) = commercialization, pricing and market share vs existing MRAs. Hidden dependencies include pricing negotiations, manufacturing scale, and potential dilution if cash falls below a 12‑month runway despite reported funding to 2028.

Trade implications: For directional exposure, prefer staged equity entry (build 1–2% portfolio weight) with buy stops on weakness below $30 and profit taking at +50% (~$55). Options: buy 12–18 month LEAP calls (e.g., Jan 2027 $40) for asymmetric upside or sell cash‑secured $30 puts (60–90d) to acquire below current levels; hedge sector beta via small short XBI position (25–50% dollar hedge). Exit/trim triggers: adverse regulatory news or share < $25.

Contrarian angles: Market may be underpricing payer/real‑world effectiveness and overpricing regulatory certainty after a single enrollment completion; the 206% run elevates downside risk — historical parallel: pre‑approval runups that retraced 60–80% on safety/label setbacks. Unintended consequence: heavy institutional accumulation can create fragile liquidity and squeeze dynamics; plan position sizing and volatility hedges accordingly.

Key Decisions for Investors

• Establish a staged long position in MLYS equal to 1–2% of portfolio: 25% of target size now, 25% at <$33, 25% at <$30, remainder allocated on material positive catalysts (NDA filing confirmation).
• Buy Jan 2027 LEAP calls (approx. 12–18 month tenor) with strike near $40 sized to 0.5–1% portfolio for leveraged upside; cap downside by using a 1:1 collar if position >1%.
• Sell cash‑secured $30 puts (60–90 day expiries) up to 0.5% portfolio to collect premium and potentially acquire MLYS below current levels; do not write puts if implied vol <40%.
• Implement a hedged pair: long MLYS (as above) and short XBI equal to 25–50% dollar exposure to reduce sector beta; trim MLYS if price >$55 or cut everything if negative regulatory outcome or price < $25.